December 10, 2013

Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

November 25, 2013

The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

October 25, 2013

A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

May 23, 2013

In anticipation of new treatments for hepatitis C, a growing number of physicians have begun intentionally delaying treatment for patients, according to a new study.

May 21, 2013

More evidence is emerging that interventions by pharmacists can have a profound beneficial effect on patient outcomes.

The latest example comes from Walgreens Specialty Pharmacy, which released the results of a study May 17 showing that more than two-thirds of patients with hepatitis C “achieved sustained virologic response or cure after completing newer ‘triple therapy’ treatment” backed up by a regimen of care and oversight by pharmacists, according to a Drug Store News report from senior editor Michael Johnsen.

Why the pharmacist interventions? They help improve patient compliance with the complicated drug therapy, which involves the administration of two newer protease inhibitors to prevent the HCV virus from reproducing, in combination with peginterferon and ribavirin. According to Johnsen, that powerful medicinal cocktail “significantly increased the cure rate and cut treatment time in half” for the 406 HCV patients in the study who received triple therapy with either telaprevir or boceprevir.

May 17, 2013

More than two-thirds of patients with hepatitis C achieved sustained virologic response or cure after completing newer “triple therapy” treatment, according to a Walgreens Specialty Pharmacy study released Friday.

May 6, 2013

An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

June 14, 2012

Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon's proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.

July 25, 2011

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


July 6, 2011

Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

June 16, 2011

Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.

May 23, 2011

The Food and Drug Administration has approved a treatment for hepatitis C made by Vertex Pharmaceuticals, the agency said Monday.

January 20, 2011

The Food and Drug Administration and Health Canada have granted priority review to a drug for treating hepatitis C.

May 25, 2010

A majority of people taking an investigational treatment for hepatitis C were cured after taking...